{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:36Z","timestamp":1781632356090,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15817"],"award-info":[{"award-number":["22K15817"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In this prospective study, we aimed to investigate the factors associated with somatostatin receptor (SSTR) expression in patients with recurrent or metastatic differentiated thyroid cancer (DTC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with DTC scheduled for\n                      <jats:sup>131<\/jats:sup>\n                      I therapy at the study institution were enrolled. The inclusion criteria required at least one assessable lesion (\u2265\u20091\u00a0cm). SSTR expression was assessed by\n                      <jats:sup>111<\/jats:sup>\n                      In-pentetreotide single-photon emission computed tomography\/computed tomography (SPECT\/CT), with Krenning scores of \u2265\u20092 considered positive. Fluorodeoxyglucose positron emission tomography (FDG PET) and post-\n                      <jats:sup>131<\/jats:sup>\n                      I therapy SPECT\/CT were also evaluated. Quantitative evaluation was performed using standardized uptake values (SUV). Clinical factors were compared between SSTR-positive and SSTR-negative patients. Spearman\u2019s correlation coefficient was calculated to evaluate the relationship between lesion size and SUVmax from\n                      <jats:sup>111<\/jats:sup>\n                      In-pentetreotide SPECT, FDG PET, and\n                      <jats:sup>131<\/jats:sup>\n                      I SPECT. Generalized estimating equations (GEEs) were utilized to identify predictors of SSTR positivity, accounting for within-patient correlation among multiple lesions. Furthermore, receiver operating characteristic (ROC) curves with clustered bootstrap resampling were used for evaluating the diagnostic performance of significant predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fourteen patients with DTC (six male; median age, 70.5 years) were evaluated, and 31 lesions were assessed. High SSTR expression was observed in 28.6% (4\/14) of patients and 51.6% (16\/31) of lesions. SSTR positivity was associated with follicular histology, elevated thyroglobulin (Tg) levels,\n                      <jats:sup>131<\/jats:sup>\n                      I uptake, larger lesion size, and bone metastasis. Using GEEs accounting for intra-patient clustering, higher\n                      <jats:sup>131<\/jats:sup>\n                      I SUVmax was the strongest independent predictor of SSTR positivity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). ROC analysis demonstrated\n                      <jats:sup>131<\/jats:sup>\n                      I SUVmax yielded a high area under the curve of 0.93 (95% confidence interval: 0.65\u20131.00) for predicting SSTR positivity. SSTR SUVmax positively correlated with lesion size (\u03c1\u2009=\u20090.67), and\n                      <jats:sup>131<\/jats:sup>\n                      I SUVmax (\u03c1\u2009=\u20090.73). Although\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG SUVmax moderately positively correlated with SSTR SUVmax (\u03c1\u2009=\u20090.49), it was not an independent predictor of SSTR positivity in GEE (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.163).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In this first study, high SSTR expression in Japanese patients with DTC was evaluated, demonstrating patients with follicular thyroid carcinoma, elevated Tg levels, larger tumor size, and positive\n                      <jats:sup>131<\/jats:sup>\n                      I uptake are more likely to have SSTR-positive lesions. These findings might support the development of novel SSTR-targeted radiopharmaceutical therapies for DTC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-026-02155-7","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:47:13Z","timestamp":1769147233000},"page":"539-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7930-0975","authenticated-orcid":false,"given":"Shiro","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-8975","authenticated-orcid":false,"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Magota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohsuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2155_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2155_CR2","doi-asserted-by":"publisher","first-page":"1412243","DOI":"10.3389\/fonc.2024.1412243","volume":"14","author":"Z Dou","year":"2024","unstructured":"Dou Z, Shi Y, Jia J. Global burden of disease study analysis of thyroid cancer burden across 204 countries and territories from 1990 to 2019. Front Oncol. 2024;14:1412243. https:\/\/doi.org\/10.3389\/fonc.2024.1412243.","journal-title":"Front Oncol"},{"key":"2155_CR3","first-page":"335","volume":"37","author":"R Dadu","year":"2012","unstructured":"Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the Art and future directions. Minerva Endocrinol. 2012;37:335\u201356.","journal-title":"Minerva Endocrinol"},{"key":"2155_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1089\/105072503322238845","volume":"13","author":"N Besic","year":"2003","unstructured":"Besic N, Vidergar-Kralj B, Frkovic-Grazio S, Movrin-Stanovnik T, Auersperg M. The role of radioactive iodine in the treatment of H\u00fcrthle cell carcinoma of the thyroid. Thyroid. 2003;13:577\u201384. https:\/\/doi.org\/10.1089\/105072503322238845.","journal-title":"Thyroid"},{"key":"2155_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram AM, Zukotynski K, Nadel HR, Giovanella L. Management of differentiated thyroid cancer: the standard of care. J Nucl Med. 2022;63:189\u201395. https:\/\/doi.org\/10.2967\/jnumed.121.262402.","journal-title":"J Nucl Med"},{"key":"2155_CR6","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892\u20139. https:\/\/doi.org\/10.1210\/jc.2005-2838.","journal-title":"J Clin Endocrinol Metab"},{"key":"2155_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"2155_CR8","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"2155_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","volume":"30","author":"DJ Kwekkeboom","year":"2003","unstructured":"Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417\u201322. https:\/\/doi.org\/10.1007\/s00259-002-1050-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2155_CR10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nrd1255","volume":"2","author":"G Weckbecker","year":"2003","unstructured":"Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999\u20131017. https:\/\/doi.org\/10.1038\/nrd1255.","journal-title":"Nat Rev Drug Discov"},{"key":"2155_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1055\/s-0029-1243636","volume":"42","author":"A Klagge","year":"2010","unstructured":"Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D. Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res. 2010;42:237\u201340. https:\/\/doi.org\/10.1055\/s-0029-1243636.","journal-title":"Horm Metab Res"},{"key":"2155_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.surg.2018.05.077","volume":"165","author":"DM Carmona Matos","year":"2019","unstructured":"Carmona Matos DM, Jang S, Hijaz B, Chang AW, Lloyd RV, Chen H, et al. Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers. Surgery. 2019;165:64\u20138. https:\/\/doi.org\/10.1016\/j.surg.2018.05.077.","journal-title":"Surgery"},{"key":"2155_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12885-021-08257-x","volume":"21","author":"Z Maghsoomi","year":"2021","unstructured":"Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer. 2021;21:579. https:\/\/doi.org\/10.1186\/s12885-021-08257-x.","journal-title":"BMC Cancer"},{"key":"2155_CR14","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754\u201362. https:\/\/doi.org\/10.1200\/JCO.2005.08.066.","journal-title":"J Clin Oncol"},{"key":"2155_CR15","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048\u201358. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229.","journal-title":"J Clin Oncol"},{"key":"2155_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12903-024-04067-2","volume":"24","author":"H Hata","year":"2024","unstructured":"Hata H, Shimomura S, Imamachi K, Sato J, Asaka T, Hirata K, et al. Stability of standardized uptake values for quantitative bone SPECT for jawbone lesions: a single-center cross-sectional study. BMC Oral Health. 2024;24:305. https:\/\/doi.org\/10.1186\/s12903-024-04067-2.","journal-title":"BMC Oral Health"},{"key":"2155_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157\u201398. https:\/\/doi.org\/10.1006\/frne.1999.0183.","journal-title":"Front Neuroendocrinol"},{"key":"2155_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000334612","volume":"95","author":"P Ameri","year":"2012","unstructured":"Ameri P, Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what\u2019s new? Neuroendocrinology. 2012;95:267\u201376. https:\/\/doi.org\/10.1159\/000334612.","journal-title":"Neuroendocrinology"},{"key":"2155_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/s0165-6147(00)88988-9","volume":"16","author":"D Hoyer","year":"1995","unstructured":"Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16:86\u20138. https:\/\/doi.org\/10.1016\/s0165-6147(00)88988-9.","journal-title":"Trends Pharmacol Sci"},{"key":"2155_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1158\/1078-0432.CCR-20-3453","volume":"27","author":"S Thakur","year":"2021","unstructured":"Thakur S, Daley B, Millo C, Cochran C, Jacobson O, Lu H, et al. 177Lu-DOTA-EB-TATE, a radiolabeled analogue of somatostatin receptor type 2, for the imaging and treatment of thyroid cancer. Clin Cancer Res. 2021;27:1399\u2013409. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3453.","journal-title":"Clin Cancer Res"},{"key":"2155_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/iep.12024","volume":"94","author":"H Atkinson","year":"2013","unstructured":"Atkinson H, England JA, Rafferty A, Jesudason V, Bedford K, Karsai L, et al. Somatostatin receptor expression in thyroid disease. Int J Exp Pathol. 2013;94:226\u20139. https:\/\/doi.org\/10.1111\/iep.12024.","journal-title":"Int J Exp Pathol"},{"key":"2155_CR22","first-page":"636","volume":"41","author":"EB Forssell-Aronsson","year":"2000","unstructured":"Forssell-Aronsson EB, Nilsson O, Bejeg\u00e5rd SA, K\u00f6lby L, Bernhardt P, M\u00f6lne J, et al. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med. 2000;41:636\u201342.","journal-title":"J Nucl Med"},{"key":"2155_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s002590050270","volume":"25","author":"E Garin","year":"1998","unstructured":"Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarc\u2019h J, Herry JY, et al. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med. 1998;25:687\u201394. https:\/\/doi.org\/10.1007\/s002590050270.","journal-title":"Eur J Nucl Med"},{"key":"2155_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/BF03351041","volume":"24","author":"LM Haslinghuis","year":"2001","unstructured":"Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 2001;24:415\u201322. https:\/\/doi.org\/10.1007\/BF03351041.","journal-title":"J Endocrinol Invest"},{"key":"2155_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1089\/105072501750362718","volume":"11","author":"R G\u00f6rges","year":"2001","unstructured":"G\u00f6rges R, Kahaly G, M\u00fcller-Brand J, M\u00e4cke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid. 2001;11:647\u201359. https:\/\/doi.org\/10.1089\/105072501750362718.","journal-title":"Thyroid"},{"key":"2155_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1186\/s12885-022-09839-z","volume":"22","author":"M Czajkowski","year":"2022","unstructured":"Czajkowski M, Kaemmerer D, S\u00e4nger J, Sauter G, Wirtz RM, Schulz S, et al. Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies. BMC Cancer. 2022;22:740. https:\/\/doi.org\/10.1186\/s12885-022-09839-z.","journal-title":"BMC Cancer"},{"key":"2155_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s00259-003-1376-x","volume":"31","author":"M Gabriel","year":"2004","unstructured":"Gabriel M, Froehlich F, Decristoforo C, Ensinger C, Donnemiller E, von Guggenberg E, et al. 99mTc-EDDA\/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging. 2004;31:330\u201341. https:\/\/doi.org\/10.1007\/s00259-003-1376-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2155_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00259-005-1820-1","volume":"32","author":"M Rodrigues","year":"2005","unstructured":"Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:1144\u201351. https:\/\/doi.org\/10.1007\/s00259-005-1820-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2155_CR29","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1210\/jc.2006-2707","volume":"92","author":"C Durante","year":"2007","unstructured":"Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92:2840\u20133. https:\/\/doi.org\/10.1210\/jc.2006-2707.","journal-title":"J Clin Endocrinol Metab"},{"key":"2155_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"N Agrawal","year":"2014","unstructured":"Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell Elsevier. 2014;159:676\u201390. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050.","journal-title":"Cell Elsevier"},{"key":"2155_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s12020-024-03779-3","volume":"85","author":"R Pishdad","year":"2024","unstructured":"Pishdad R, Treglia G, Mehta A, Santhanam P. Somatostatin receptor imaging of thyroid tissue and differentiated thyroid cancer using gallium-68-labeled radiotracers-a review of clinical studies. Endocrine. 2024;85:566\u201375. https:\/\/doi.org\/10.1007\/s12020-024-03779-3.","journal-title":"Endocrine"},{"key":"2155_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1056\/NEJM199601253340408","volume":"334","author":"SW Lamberts","year":"1996","unstructured":"Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ, Octreotide. N Engl J Med. 1996;334:246\u201354. https:\/\/doi.org\/10.1056\/NEJM199601253340408.","journal-title":"N Engl J Med"},{"key":"2155_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Sch\u00e4r JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273\u201382. https:\/\/doi.org\/10.1007\/s002590050034.","journal-title":"Eur J Nucl Med"},{"key":"2155_CR34","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1210\/jcem.81.7.8675574","volume":"81","author":"E Baudin","year":"1996","unstructured":"Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab. 1996;81:2541\u20134. https:\/\/doi.org\/10.1210\/jcem.81.7.8675574.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2155_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000201391","volume":"57","author":"PT Postema","year":"1996","unstructured":"Postema PT, De Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ, et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion. 1996;57(Suppl 1):36\u20137. https:\/\/doi.org\/10.1159\/000201391.","journal-title":"Digestion"},{"key":"2155_CR36","first-page":"76","volume":"54","author":"M Middendorp","year":"2010","unstructured":"Middendorp M, Selkinski I, Happel C, Kranert WT, Gr\u00fcnwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54:76\u201383.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2155_CR37","first-page":"1468","volume":"37","author":"U Feine","year":"1996","unstructured":"Feine U, Lietzenmayer R, Hanke JP, Held J, W\u00f6hrle H, M\u00fcller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468\u201372.","journal-title":"J Nucl Med"},{"key":"2155_CR38","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2967\/jnumed.115.171942","volume":"57","author":"I Binse","year":"2016","unstructured":"Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, G\u00f6rges R, Sabet A, et al. 68Ga-DOTATOC PET\/CT in patients with Iodine- and 18F-FDG-Negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J Nucl Med. 2016;57:1512\u20137. https:\/\/doi.org\/10.2967\/jnumed.115.171942.","journal-title":"J Nucl Med"},{"key":"2155_CR39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1530\/ERC-21-0052","volume":"28","author":"C Borga","year":"2021","unstructured":"Borga C, Dal Pozzo CA, Trevellin E, Bergamo F, Murgioni S, Milanetto AC, et al. mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs. Endocr Relat Cancer. 2021;28:449\u201356. https:\/\/doi.org\/10.1530\/ERC-21-0052.","journal-title":"Endocr Relat Cancer"},{"key":"2155_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/107327480601300108","volume":"13","author":"A Nasir","year":"2006","unstructured":"Nasir A, Stridsberg M, Strosberg J, Su P-H, Livingston S, Malik HA, et al. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control. 2006;13:52\u201360. https:\/\/doi.org\/10.1177\/107327480601300108.","journal-title":"Cancer Control"},{"key":"2155_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00428-017-2093-3","volume":"470","author":"M Charoenpitakchai","year":"2017","unstructured":"Charoenpitakchai M, Liu E, Zhao Z, Koyama T, Huh WJ, Berlin J, et al. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. Virchows Arch. 2017;470:545\u201352. https:\/\/doi.org\/10.1007\/s00428-017-2093-3.","journal-title":"Virchows Arch"},{"key":"2155_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1089\/thy.2013.0225","volume":"24","author":"A Versari","year":"2014","unstructured":"Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid. 2014;24:715\u201326. https:\/\/doi.org\/10.1089\/thy.2013.0225.","journal-title":"Thyroid"},{"key":"2155_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.nucmedbio.2014.12.006","volume":"42","author":"C Lapa","year":"2015","unstructured":"Lapa C, Werner RA, Schmid J-S, Papp L, Zs\u00f3t\u00e9r N, Biko J, et al. Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. Nucl Med Biol. 2015;42:349\u201354. https:\/\/doi.org\/10.1016\/j.nucmedbio.2014.12.006.","journal-title":"Nucl Med Biol"},{"key":"2155_CR44","first-page":"813","volume":"49","author":"S Takano","year":"2022","unstructured":"Takano S, Kobayashi N, Ichikawa Y, Hata M. [Indications and practice of a new radionuclide Therapy, 177Lu-DOTATATE in Japan]. Gan Kagaku Ryoho. 2022;49:813\u201320.","journal-title":"Gan Kagaku Ryoho"},{"key":"2155_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrc1836","volume":"6","author":"T Kondo","year":"2006","unstructured":"Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6:292\u2013306. https:\/\/doi.org\/10.1038\/nrc1836.","journal-title":"Nat Rev Cancer"},{"key":"2155_CR46","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1210\/clinem\/dgab286","volume":"106","author":"Y Tao","year":"2021","unstructured":"Tao Y, Wang F, Shen X, Zhu G, Liu R, Viola D, et al. BRAF V600E status sharply differentiates lymph node Metastasis-associated mortality risk in papillary thyroid cancer. J Clin Endocrinol Metab. 2021;106:3228\u201338. https:\/\/doi.org\/10.1210\/clinem\/dgab286.","journal-title":"J Clin Endocrinol Metab"},{"key":"2155_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1507\/endocrj.k08e-208","volume":"56","author":"Y Ito","year":"2009","unstructured":"Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89\u201397. https:\/\/doi.org\/10.1507\/endocrj.k08e-208.","journal-title":"Endocr J"},{"key":"2155_CR48","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3803\/EnM.2015.30.3.252","volume":"30","author":"YS Song","year":"2015","unstructured":"Song YS, Lim JA, Park YJ. Mutation profile of Well-Differentiated thyroid cancer in Asians. Endocrinol Metab (Seoul). 2015;30:252\u201362. https:\/\/doi.org\/10.3803\/EnM.2015.30.3.252.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2155_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fmed.2019.00024","volume":"6","author":"P Thuillier","year":"2019","unstructured":"Thuillier P, Bourhis D, Roudaut N, Crouzeix G, Alavi Z, Schick U, et al. Diagnostic value of FDG PET-CT quantitative parameters and Deauville-Like 5 Point-Scale in predicting malignancy of focal thyroid incidentaloma. Front Med (Lausanne). 2019;6:24. https:\/\/doi.org\/10.3389\/fmed.2019.00024.","journal-title":"Front Med (Lausanne)"},{"key":"2155_CR50","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2214\/AJR.19.22642","volume":"215","author":"KP Banks","year":"2020","unstructured":"Banks KP, Peacock JG, Gusman M, Clemenshaw MN. It\u2019s about Quality, not quantity: qualitative FDG PET\/CT criteria for therapy response assessment in clinical practice. Am J Roentgenol Am Roentgen Ray Soc. 2020;215:313\u201324. https:\/\/doi.org\/10.2214\/AJR.19.22642.","journal-title":"Am J Roentgenol Am Roentgen Ray Soc"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02155-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:59:49Z","timestamp":1781629189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02155-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2155"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02155-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}